|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 39/395 | |
| A61K 31/716 | |||
| A61P 35/00 | |||
| A61K 45/00 |
| (11) | Patento numeris | 2461870 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10802912.5 |
| Europos patento paraiškos padavimo data | 2010-07-22 | |
| (97) | Europos patento paraiškos paskelbimo data | 2012-06-13 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-09-06 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2010/042925 |
| Data | 2010-07-22 |
| (87) | Numeris | WO 2011/011617 |
| Data | 2011-01-27 |
| (30) | Numeris | Data | Šalis |
| 271514 P | 2009-07-22 | US |
| (72) |
VASILAKOS, John, P., US
|
| (73) |
Biothera, Inc.,
3388 Mike Collins Drive, Eagan, MN 55121,
US
|
| (54) | COMPOSITION COMPRISING BETA-GLUCAN AND AN EGF-R ANTIBODY OR AN EGF-R ANTAGONIST FOR USE IN THE TREATMENT OF KRAS-MUTATED TUMORS |
| COMPOSITION COMPRISING BETA-GLUCAN AND AN EGF-R ANTIBODY OR AN EGF-R ANTAGONIST FOR USE IN THE TREATMENT OF KRAS-MUTATED TUMORS |